A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
NCT ID: NCT04965870
Last Updated: 2022-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2021-06-30
2021-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
NCT02830139
Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras
NCT01651013
Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.
NCT03914820
Second Look Laparoscopy in Colorectal Cancer
NCT01628211
RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer
NCT02502656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trifluridine/Tipiracil
Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed metastatic colorectal cancer
* Available data on previous chemotherapy lines
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Servier
INDUSTRY
Hellenic Study Group of Psychoneuroimmunology in Cancer
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ANNA KOUMARIANOU, PhD
Role: PRINCIPAL_INVESTIGATOR
4th Department of Internal Medicine, Attikon University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University General Hospital of Heraklion (PAGNI)
Heraklion, Crete, Greece
General Hospital "Venizeleio - Pananio"
Heraklion, Crete, Greece
Athens Medical Group
Athens, , Greece
General Oncological Hospital "Agioi Anargyroi"
Athens, , Greece
Agios Savvas Cancer Hospital
Athens, , Greece
Attikon University Hospital
Athens, , Greece
Anticancer Hospital "METAXA"
Piraeus, , Greece
Bioclinic
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.